Correspondence

Comment on Progression of Retinopathy Secondary to Maternally Inherited Diabetes and Deafness: Evaluation of Predicting Parameters

WE READ THE ARTICLE BY MÜLLER AND COLLEAGUES[1] WITH great interest about the investigation of the prognostic value of demographic, functional, and imaging parameters on retinal pigment epithelium (RPE) atrophy progression in patients with maternally inherited diabetes and deafness (MIDD) syndrome and to evaluate the application of these factors on clinical trial design. It was concluded that RPE atrophy had a significant prognostic value in MIDD patients.[1] Their study has a number of shortcomings and raises concerns.

The main shortcoming of the study is that heteroplasmy rates were not considered as a factor of RPE atrophy progression and were thus not included in the calculation of the factors determining RPE atrophy progression. Knowing heteroplasmy rates in different tissues, such as hair follicles, buccal mucosa cells, skin fibroblasts, myocytes, lymphocytes, and urinary epithelial cells, is crucial as they may strongly determine the phenotypic expression and the disease course in patients carrying mtDNA variants.[2] According to these findings it is conceivable that high heteroplasmy rates are associated with more rapid progression of RPE atrophy than low levels. Additionally, we should be informed about the haplotypes of the 20 patients and whether mtDNA sequencing revealed other pathogenic or nonpathogenic mtDNA variants. Knowing the mtDNA status is crucial as the m.3243A>G variant may not be the only variant responsible for the phenotypic expression.

A further shortcoming is that the current medication each patient was regularly taking was not considered in the calculation of factors determining RPE atrophy progression. Antidiabetics and antioxidants may strongly influence the speed of RPE atrophy progression. Knowing the type and dosage of drugs of all patients is crucial as these drugs may strongly influence the pathogenicity of the causative mtDNA variant. As mentioned in the introduction, antioxidants have been shown to be potentially beneficial for ophthalmologic manifestations of mtDNA variants.[3]

Because MIDD may accompany lactic acidosis,[4] we should also be informed about how many of the 20 patients had elevated serum or cerebrospinal fluid (CSF) lactate levels. Knowing serum/CSF lactate values is crucial as many diabetic patients receive metformin, which is known to elevate serum/CSF lactate.[5]

We should also know the HbA1c values of the patients, as the quality of diabetes control may contribute to the disease progression and thus increase of RPE atrophy.[2]

Unfortunately, the authors did not consider multisystem involvement in MIDD. MIDD patients frequently manifest not only in the pancreas and the ears but variably also in a number of other organs, structures, and tissues.[6] Ophthalmologic manifestations other than RPE atrophy may include the optic nerve, the central retinal vein occlusion, or retinal choroidal atrophy.[6] Optic nerve hypoplasia has been reported in 12% of the nonsyndromic mitochondrial disorders.

In conclusion, this interesting study has a number of limitations which need to be solved before conclusions as presented in the article can be drawn. To calculate endpoints by application of a multiregression analysis, additional parameters, such as those outlined above, need to be integrated in the model. RPE atrophy is currently not a suitable endpoint of MIDD.

JOSEF FINSTERER
Vienna, Austria
FULVIO A. SCORZA
CARLA A. SCORZA
São Paulo, Brazil

REFERENCES

1. Müller PL, Treis T, Pfau M, et al. Progression of retinopathy secondary to maternally inherited diabetes and deafness— evaluation of predicting parameters. *Am J Ophthalmol* 2020; 213:134–144.
2. Laloi-Michelin M, Meas T, Ambonville C, et al; for the Mitochondrial diabetes French Study Group. The clinical variability of maternally inherited diabetes and deafness is associated with the degree of heteroplasmy in blood leukocytes. *J Clin Endocrinol Metab* 2009;94:3025–3030.
3. Rickmann A, Wocker L, Damm LJ, Ivanescu C, Szurman P, Pérez Guerra N. LHON-treatment option despite poor initial visual acuity? *Ophthalmologe* 2019;116:970–974.
4. Fromont I, Nicoli F, Valéro R, et al. Brain anomalies in maternally inherited diabetes and deafness syndrome. *J Neurol* 2009; 256:1696–1704.

5. Yendapally R, Sikazwe D, Kim SS, et al. A review of phenformin, metformin, and imeglimin. *Drug Dev Res* 2020;81(4):390–401.
6. Finsterer J, Frank M. The tip of the iceberg in maternally inherited diabetes and deafness. *Oman Med J* 2018;33:437–440.

Reply to Comment on: Progression of Retinopathy Secondary to Maternally Inherited Diabetes and Deafness – Evaluation of Predicting Parameters

REPLY

MATERNALLY INHERITED DIABETES AND DEAFNESS (MIDD) presents with different phenotypes associated with the individual percentage of affected mitochondria (heteroplasmy).[1,2] In this study we demonstrated that atrophy of the retinal pigment epithelium (RPE) is a meaningful and reliable endpoint that allows for designing proof-of-concept clinical trials with small numbers of patients.[3]

Drs Finsterer and Scorza seem to miss much of the intent of our article. Instead they want to state that MIDD is due not only to m.3243A>G mutation but to other mutations, which, while interesting, has no relevance to the focus of the article. A second point they want to establish is that MIDD can affect organs other than the eyes, which is widely known and already mentioned in our manuscript. Actually, this is the point of the manuscript, as extraocular manifestations of MIDD are problematic in terms of potential endpoints for clinical trials.

In addition, they requested to know the heteroplasmy rate of each patient. While we agree that knowing tissue-relevant rates of heteroplasmy would be of interest, as it is understood that the heteroplasmy rate differs from one tissue to the other, retinal tissue must be obtained, as peripheral tissue heteroplasmy rates may not relate to that of the RPE. Given that we are dealing with living humans with MIDD in this study, we would need to undertake a macular retina/RPE biopsy; this might not only be ethically incorrect but also sight-threatening, while not leading to any change in our conclusions. As non-ophthalmologists, Drs Finsterer and Scorza may not be aware of this issue of biopsy risk. Dr Finsterer refers to a study by Laloi-Michelin and associates to support the importance of measuring heteroplasmy rates of blood lymphocytes on retinopathy. However, this report shows the converse and argues against his point, in that about the same proportion (three quarters) of eyes with the highest heteroplasmy levels and the rest of eyes had macular pattern dystrophy.[2] In addition, Dr Finsterer demonstrates inconsistency, as he has previously argued against the utility of heteroplasmy in ocular studies, as he previously stated in the correspondence to Spaide that correlation between heteroplasmic mtDNA point mutations and clinical severity is usually poor[4] and is associated with marked phenotypic heterogeneity between family members and between generations.[5]

The medical history and daily medication of every patient might be nice to have. Giving the retrospective character of our article, we might include this as a factor for further upcoming prospective studies. Finally, Drs Finsterer and Scorza mentioned the lactate value in the cerebrospinal fluid of MIDD patients. It is not evident how this statement is germane to the focus of our article given the differences in retina/RPE vs central nervous system metabolism.[6]

They finish their comment by stating that "RPE atrophy is currently no suitable endpoint of MIDD." As shown in this reply, this statement is based on an untenable argument. As we could show throughout our manuscript, RPE atrophy is indeed a reliable and suitable endpoint for disease progression and, therefore, treatment effects. It is simple to quantify, in contrast to other endpoints both ocular and nonocular, and is an accepted endpoint by the U.S. Food and Drug Administration and European Medicines Agency for other ocular conditions.

PHILIPP L. MÜLLER
London, United Kingdom
Bonn, Germany
ADNAN TUFAIL
London, United Kingdom

REFERENCES

1. 't Hart LM, Jansen JJ, Lemkes HHPJ, de Knijff P, Maassen JA. Heteroplasmy levels of a mitochondrial gene mutation associated with diabetes mellitus decrease in leucocyte DNA upon aging. *Hum Mutat* 1996;7(3):193–197.
2. Laloi-Michelin M, Meas T, Ambonville C, et al. The clinical variability of maternally inherited diabetes and deafness is associated with the degree of heteroplasmy in blood leukocytes. *J Clin Endocrinol Metab* 2009;94(8):3025–3030.
3. Müller PL, Treis T, Pfau M, et al. Progression of retinopathy secondary to maternally inherited diabetes and deafness – evaluation of predicting parameters. *Am J Ophthalmol* 2020;213:134–144.
4. Alston CL, Rocha MC, Lax NZ, Turnbull DM, Taylor RW. The genetics and pathology of mitochondrial disease. *J Pathol* 2017;241(2):236–250.
5. Spaide RF. Reply. *Retina* 2017;37(6):e89–e90.
6. Hurley JB, Lindsay KJ, Du J. Glucose, lactate, and shuttling of metabolites in vertebrate retinas. *J Neurosci Res* 2015;93(7):1079–1092.